Oncologix SRL
Oncologix reported total assets of 53,513 € at the end of the 2025 financial year (annual accounts filed with the NBB on 28 Aug 2026).
The score of Oncologix shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Accounts of the company itself (not consolidated).
Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Oncologix's annual accounts
| 2025 | |
|---|---|
| Net result | 29,775 € |
| Equity | 29,776 € |
| Cash | 11,941 € |
| EBITDA | 37,455 € |
| Total assets | 53,513 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 28 Aug 2026
Oncologix's financial analysis
- Solvency55.6%sector median: 45.7%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Oncologix
Oncologix's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 1027.890.093
- VAT number
- BE1027890093
- Peppol
- Registered · 0208:1027890093 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 19 Sep 2025
- Registered office
- 1050 Ixelles
- Latest accounts
- 2025 · filed on 28 Aug 2026
- Activity
- Research and experimental development on other natural sciences and engineering (NACE 72109)
Oncologix (SRL) has been based in Ixelles since 2025, active in: research and experimental development on other natural sciences and engineering. For 2025, it reports a net profit of 29,775 € and equity of 29,776 €; its revenue is not published. Its solvency stands at 55.6%, above the median of its sector (45.7%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Oncologix
Companies in the same business, of comparable size and area, outside its group.
- Neurologie AZORG Research and experimental development on natural sciences and engineering Aalst · balance sheet 759,096 €
- ChiLi & Co Research and experimental development on natural sciences and engineering Izegem · balance sheet 61,476 €
- AtomX Research and experimental development on natural sciences and engineering Chastre · balance sheet 32,717 €
- United Beers Research and experimental development on natural sciences and engineering Evergem · balance sheet 97,439 €
- Darwinula Research and experimental development on natural sciences and engineering Ghent · balance sheet 43,391 €
- Trenker Nutrition Research and experimental development on natural sciences and engineering Nivelles · balance sheet 72,988 €
- Tewane Pharma Research and experimental development on natural sciences and engineering Braine-l'Alleud · balance sheet 149,853 €
- Cmax Biotech Consulting Research and experimental development on natural sciences and engineering Hasselt · balance sheet 52,078 €
Frequently asked questions about Oncologix
What is the revenue of Oncologix?
Oncologix files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Oncologix?
In Belgium, the VAT number is the company number prefixed with BE: BE1027890093 for Oncologix, if the company is VAT-registered. Its company number (CBE) is 1027.890.093.
Where is the registered office of Oncologix?
According to the CBE register, the registered office of Oncologix is in 1050 Ixelles.
What is the equity of Oncologix?
At the close of the 2025 financial year, the equity of Oncologix amounts to 29,776 €, a solvency of 55.6% of total assets.
Who manages Oncologix?
The register lists 1 active mandates at Oncologix. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Oncologix
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →